173 related articles for article (PubMed ID: 32004164)
1. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
[TBL] [Abstract][Full Text] [Related]
2. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
3. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
4. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
Colomba C; Rubino R; Siracusa L; Lalicata F; Trizzino M; Titone L; Tolomeo M
BMC Res Notes; 2012 Oct; 5():552. PubMed ID: 23039051
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy.
Benevolo G; Elli EM; Guglielmelli P; Ricco A; Maffioli M
Leuk Lymphoma; 2020 Jul; 61(7):1535-1547. PubMed ID: 32093511
[TBL] [Abstract][Full Text] [Related]
6. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
7. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review.
Khalid F; Damlaj M; AlZahrani M; Abuelgasim KA; Gmati GE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):252-256. PubMed ID: 32201152
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Palandri F; Polverelli N; Catani L; Vianelli N
Ann Hematol; 2015 Mar; 94(3):519-20. PubMed ID: 25172457
[No Abstract] [Full Text] [Related]
10. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M; Giorgino T; Mora B; Iurlo A; Elli E; Finazzi MC; Caramella M; Rumi E; Carraro MC; Polverelli N; D'Adda M; Malato S; Rossi M; Molteni A; Vismara A; Sissa C; Spina F; Anghilieri M; Cattaneo D; Renso R; Bellini M; Pioltelli ML; Cavalloni C; Barraco D; Accetta R; Bertù L; Della Porta MG; Passamonti F
Blood Adv; 2019 Nov; 3(21):3196-3200. PubMed ID: 31698448
[TBL] [Abstract][Full Text] [Related]
13. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
[TBL] [Abstract][Full Text] [Related]
14. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
15. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
16. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Polverelli N; Elli EM; Abruzzese E; Palumbo GA; Benevolo G; Tiribelli M; Bonifacio M; Tieghi A; Caocci G; D'Adda M; Bergamaschi M; Binotto G; Heidel FH; Cavazzini F; Crugnola M; Pugliese N; Bosi C; Isidori A; Bartoletti D; Auteri G; Latagliata R; Gandolfi L; Martino B; Scaffidi L; Cattaneo D; D'Amore F; Trawinska MM; Stella R; Markovic U; Catani L; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Vianelli N; Breccia M; Russo D; Cavo M; Iurlo A; Palandri F
Br J Haematol; 2021 Apr; 193(2):356-368. PubMed ID: 33222197
[TBL] [Abstract][Full Text] [Related]
17. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
18. Occult hepatitis B infection reactivation after ruxolitinib therapy.
Perricone G; Vinci M; Pungolino E
Dig Liver Dis; 2017 Jun; 49(6):719. PubMed ID: 28410914
[No Abstract] [Full Text] [Related]
19. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review.
Chen CY; Chen TC
Medicine (Baltimore); 2024 Apr; 103(14):e37653. PubMed ID: 38579059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
